Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities.
IL-6
YKL-40
bone metastases
inflammatory response
prognostic biomarkers
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Jun 2021
07 Jun 2021
Historique:
received:
20
05
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014-2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58-74; female 51%) were included. Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD.
Sections du résumé
BACKGROUND
BACKGROUND
Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities.
PATIENTS AND METHODS
METHODS
A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014-2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58-74; female 51%) were included.
RESULTS
RESULTS
Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46,
CONCLUSION
CONCLUSIONS
High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD.
Identifiants
pubmed: 34200156
pii: cancers13112833
doi: 10.3390/cancers13112833
pmc: PMC8201042
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Brøderne Hartmanns foundation
ID : none
Organisme : Capital Region of Denmark Research and Innovation foundation
ID : None
Organisme : Centre of Head and Orthopedics, Rigshospitalet
ID : None
Organisme : Board of management Rigshospitalet
ID : None
Organisme : Lykfeldt's legat
ID : None
Références
Injury. 2007 Mar;38 Suppl 1:S11-25
pubmed: 17383481
Protein Sci. 1997 May;6(5):929-55
pubmed: 9144766
J Hematol Oncol. 2017 Feb 1;10(1):36
pubmed: 28143526
Clin Orthop Relat Res. 2013 Mar;471(3):843-50
pubmed: 22983682
Clin Chim Acta. 2011 Apr 11;412(9-10):709-12
pubmed: 21272568
Front Oncol. 2020 Oct 22;10:566511
pubmed: 33194645
Biomarkers. 2008 Feb;13(1):59-78
pubmed: 17852075
J Leukoc Biol. 2015 Dec;98(6):931-6
pubmed: 26310833
Oncotarget. 2018 Jul 3;9(51):29820-29841
pubmed: 30038723
J Surg Oncol. 2017 Mar;115(4):442-448
pubmed: 28019011
Acta Oncol. 2019 Apr;58(4):456-462
pubmed: 30632859
Clin Orthop Relat Res. 2020 Mar;478(3):607-615
pubmed: 31702689
J Bone Joint Surg Am. 2018 Feb 7;100(3):196-204
pubmed: 29406340
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114676
Biochem Biophys Res Commun. 1988 Nov 30;157(1):271-7
pubmed: 2461709
Cancer Cell Int. 2019 Oct 10;19:259
pubmed: 31624472
Cancer Med. 2014 Oct;3(5):1359-67
pubmed: 25044999
Bone Joint J. 2016 Feb;98-B(2):271-7
pubmed: 26850435
Clin Orthop Relat Res. 2013 Jun;471(6):2000-6
pubmed: 23247815
Signal Transduct Target Ther. 2020 Sep 14;5(1):201
pubmed: 32929074
Future Oncol. 2009 Sep;5(7):1065-82
pubmed: 19792974
Pharmacol Ther. 2019 Nov;203:107394
pubmed: 31356910
Br J Anaesth. 1996 Aug;77(2):217-22
pubmed: 8881629
Medicine (Baltimore). 2016 Apr;95(15):e3354
pubmed: 27082592
Immunol Cell Biol. 2014 Apr;92(4):331-9
pubmed: 24751614